212 related articles for article (PubMed ID: 16846532)
1. Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients.
Calza S; Hall P; Auer G; Bjöhle J; Klaar S; Kronenwett U; Liu ET; Miller L; Ploner A; Smeds J; Bergh J; Pawitan Y
Breast Cancer Res; 2006; 8(4):R34. PubMed ID: 16846532
[TBL] [Abstract][Full Text] [Related]
2. Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling.
Van Laere SJ; Van den Eynden GG; Van der Auwera I; Vandenberghe M; van Dam P; Van Marck EA; van Golen KL; Vermeulen PB; Dirix LY
Breast Cancer Res Treat; 2006 Feb; 95(3):243-55. PubMed ID: 16261404
[TBL] [Abstract][Full Text] [Related]
3. GATA3 mutations define a unique subtype of luminal-like breast cancer with improved survival.
Jiang YZ; Yu KD; Zuo WJ; Peng WT; Shao ZM
Cancer; 2014 May; 120(9):1329-37. PubMed ID: 24477928
[TBL] [Abstract][Full Text] [Related]
4. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
Zhang HM; Zhang BN; Xuan LX; Zhao P
Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
[TBL] [Abstract][Full Text] [Related]
5. Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response.
de Ronde JJ; Hannemann J; Halfwerk H; Mulder L; Straver ME; Vrancken Peeters MJ; Wesseling J; van de Vijver M; Wessels LF; Rodenhuis S
Breast Cancer Res Treat; 2010 Jan; 119(1):119-26. PubMed ID: 19669409
[TBL] [Abstract][Full Text] [Related]
6. [Clinical features and prognosis analysis of different breast cancer molecular subtypes].
Yang Q; Chen J; Li HJ; Yu M; Tian CX; Lü Q
Zhonghua Zhong Liu Za Zhi; 2011 Jan; 33(1):42-6. PubMed ID: 21575463
[TBL] [Abstract][Full Text] [Related]
7. Identification of different subtypes of breast cancer using tissue microarray.
Munirah MA; Siti-Aishah MA; Reena MZ; Sharifah NA; Rohaizak M; Norlia A; Rafie MK; Asmiati A; Hisham A; Fuad I; Shahrun NS; Das S
Rom J Morphol Embryol; 2011; 52(2):669-77. PubMed ID: 21655659
[TBL] [Abstract][Full Text] [Related]
8. Nonfamilial breast cancer subtypes.
Ringnér M; Staaf J; Jönsson G
Methods Mol Biol; 2013; 973():279-95. PubMed ID: 23412797
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
10. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer classification according to immunohistochemistry markers: subtypes and association with clinicopathologic variables in a peruvian hospital database.
Vallejos CS; Gómez HL; Cruz WR; Pinto JA; Dyer RR; Velarde R; Suazo JF; Neciosup SP; León M; de la Cruz MA; Vigil CE
Clin Breast Cancer; 2010 Aug; 10(4):294-300. PubMed ID: 20705562
[TBL] [Abstract][Full Text] [Related]
12. A genetic signature can predict prognosis and response to therapy in breast cancer: Oncotype DX.
Kaklamani V
Expert Rev Mol Diagn; 2006 Nov; 6(6):803-9. PubMed ID: 17140367
[TBL] [Abstract][Full Text] [Related]
13. Apoptosis-, proliferation, immune function-, and drug resistance- related genes in ER positive, HER2 positive and triple negative breast cancer.
Kolacinska A; Chalubinska J; Zawlik I; Szymanska B; Borowska-Garganisz E; Nowik M; Fendler W; Kubiak R; Pawlowska Z; Morawiec Z; Szemraj J
Neoplasma; 2012; 59(4):424-32. PubMed ID: 22489698
[TBL] [Abstract][Full Text] [Related]
14. The erbB2+ cluster of the intrinsic gene set predicts tumor response of breast cancer patients receiving neoadjuvant chemotherapy with docetaxel, doxorubicin and cyclophosphamide within the GEPARTRIO trial.
Rody A; Karn T; Solbach C; Gaetje R; Munnes M; Kissler S; Ruckhäberle E; Minckwitz GV; Loibl S; Holtrich U; Kaufmann M
Breast; 2007 Jun; 16(3):235-40. PubMed ID: 17449250
[TBL] [Abstract][Full Text] [Related]
15. An integrative hypothesis about the origin and development of sporadic and familial breast cancer subtypes.
Melchor L; Benítez J
Carcinogenesis; 2008 Aug; 29(8):1475-82. PubMed ID: 18596026
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study.
Sanpaolo P; Barbieri V; Genovesi D
Eur J Surg Oncol; 2011 Oct; 37(10):876-82. PubMed ID: 21824742
[TBL] [Abstract][Full Text] [Related]
17. Distinct genomic aberration patterns are found in familial breast cancer associated with different immunohistochemical subtypes.
Melchor L; Honrado E; García MJ; Alvarez S; Palacios J; Osorio A; Nathanson KL; Benítez J
Oncogene; 2008 May; 27(22):3165-75. PubMed ID: 18071313
[TBL] [Abstract][Full Text] [Related]
18. Molecular biology in breast cancer: intrinsic subtypes and signaling pathways.
Eroles P; Bosch A; Pérez-Fidalgo JA; Lluch A
Cancer Treat Rev; 2012 Oct; 38(6):698-707. PubMed ID: 22178455
[TBL] [Abstract][Full Text] [Related]
19. High-resolution genomic profiles of breast cancer cell lines assessed by tiling BAC array comparative genomic hybridization.
Jönsson G; Staaf J; Olsson E; Heidenblad M; Vallon-Christersson J; Osoegawa K; de Jong P; Oredsson S; Ringnér M; Höglund M; Borg A
Genes Chromosomes Cancer; 2007 Jun; 46(6):543-58. PubMed ID: 17334996
[TBL] [Abstract][Full Text] [Related]
20. Gene expression profiling assigns CHEK2 1100delC breast cancers to the luminal intrinsic subtypes.
Nagel JH; Peeters JK; Smid M; Sieuwerts AM; Wasielewski M; de Weerd V; Trapman-Jansen AM; van den Ouweland A; Brüggenwirth H; van I Jcken WF; Klijn JG; van der Spek PJ; Foekens JA; Martens JW; Schutte M; Meijers-Heijboer H
Breast Cancer Res Treat; 2012 Apr; 132(2):439-48. PubMed ID: 21614566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]